BRD9: A Potential Drug Target for Breast Cancer (G65980)

Target Name: BRD9

NCBI ID: G65980

BRD9

BRD9: A Potential Drug Target for Breast Cancer

BRD9 (Breast cancer resistance protein 9) is a protein that is expressed in breast tissue and has been identified as a potential drug target for breast cancer. BRD9 is a transmembrane protein that is involved in cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of breast cancer.

BRD9 is a glycoprotein that consists of 196 amino acids. It is expressed in a variety of tissues, including breast tissue, lymphoid tissue, and bone marrow. It is also expressed in various cell types, including epithelial cells, endothelial cells, and immune cells.

BRD9 is involved in cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of breast cancer. TGF-β is a cytokine that is involved in the regulation of cell growth, cell differentiation, and cell survival. It is a transcription factor that regulates the expression of genes that are involved in cell signaling and growth.

BRD9 is a potential drug target for breast cancer because it is involved in the TGF-β pathway, which is a key factor in the development and progression of this disease. Studies have shown that inhibiting the activity of TGF-β signaling pathways can be an effective way to treat breast cancer. In addition, BRD9 has been shown to be overexpressed in various types of breast cancer, which suggests that it may be a useful biomarker for this disease.

BRD9 is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. It is important for the development and maintenance of tissues and organs, and is a key factor in the development and progression of many diseases, including breast cancer.

BRD9 is involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of breast cancer. TGF-β is a cytokine that is involved in the regulation of cell growth, cell differentiation, and cell survival. It is a transcription factor that regulates the expression of genes that are involved in cell signaling and growth.

BRD9 is a glycoprotein that consists of 196 amino acids. It is expressed in a variety of tissues, including breast tissue, lymphoid tissue, and bone marrow. It is also expressed in various cell types, including epithelial cells, endothelial cells, and immune cells.

BRD9 is involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. It is important for the development and maintenance of tissues and organs, and is a key factor in the development and progression of many diseases, including breast cancer.

BRD9 is also involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of breast cancer. TGF-β is a cytokine that is involved in the regulation of cell growth, cell differentiation, and cell survival. It is a transcription factor that regulates the expression of genes that are involved in cell signaling and growth.

BRD9 is a potential drug target for breast cancer because it is involved in the TGF-β pathway, which is a key factor in the development and progression of this disease. Studies have shown that inhibiting the activity of TGF-β signaling pathways can be an effective way to treat breast cancer. In addition, BRD9 has been shown to be overexpressed in various types of breast cancer, which suggests that it may be a useful biomarker for this disease.

In conclusion, BRD9 is a protein that is expressed in breast tissue and has been identified as a potential drug target for breast cancer. It is involved in cell signaling pathways, including the TGF-β pathway, and is involved in the regulation of cell adhesion. Studies have shown that inhibiting the activity of TGF-β signaling pathways can be an effective way to treat breast cancer, and BRD9 has been shown to be overexpressed in various types of breast cancer, which suggests that it may be a useful biomarker for this disease. Further research is needed to fully understand the role of BRD9 as a potential drug target for breast cancer.

Protein Name: Bromodomain Containing 9

Functions: Plays a role in chromatin remodeling and regulation of transcription (PubMed:22464331, PubMed:26365797). Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated (PubMed:26365797). Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058). Orchestrates also the RAD51-RAD54 complex formation and thereby plays a role in homologous recombination (HR) (PubMed:32457312)

The "BRD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets